Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Study of a High-Risk Group of Stage II Colon Cancer
    Hirosawa, Tomoichiro
    Itabashi, Michio
    Bamba, Yoshiko
    Ogawa, Shinpei
    Sirotani, Noriyasu
    Kameoka, Shingo
    INTERNATIONAL SURGERY, 2009, 94 (02) : 130 - 135
  • [32] Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis
    Ejaz, Aslam
    Casadaban, Leigh
    Maker, Ajay V.
    JOURNAL OF SURGICAL RESEARCH, 2017, 215 : 12 - 20
  • [33] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Liao, Leen
    Tang, Jinghua
    Hong, Zhigang
    Jiang, Wu
    Li, Yuan
    Kong, Lingheng
    Han, Kai
    Hou, Zhenlin
    Zhang, Chenzhi
    Zhou, Chi
    Zhang, Linjie
    Sui, Qiaoqi
    Xiao, Binyi
    Mei, Weijian
    Yu, Jiehai
    Yang, Wanjun
    Pan, Zhizhong
    Ding, Pei-Rong
    BMC CANCER, 2024, 24 (01)
  • [34] Clinical Decision Support for High-Risk Stage II Colon Cancer: A Real-World Study of Treatment Concordance and Survival
    Chen, Peng-ju
    Li, Tian-le
    Sun, Ting-ting
    Willis, Van C.
    Roebuck, M. Christopher
    Bravata, Dena M.
    Liu, Xin-zhi
    Arriaga, Yull E.
    Dankwa-Mullan, Irene
    Wu, Ai-wen
    DISEASES OF THE COLON & RECTUM, 2020, 63 (10) : 1383 - 1392
  • [35] The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II-III Colorectal Cancer: A Retrospective Multi-Center Cohort Study
    Liu, Lizhu
    Pang, Xiaolin
    Zhao, Ke
    Chen, Yaxue
    Li, Yanli
    You, Ruimin
    Xu, Tingting
    Liu, Mengmei
    Wu, Lin
    Li, Zhenhui
    Pu, Hongjiang
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 3311 - 3322
  • [36] A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer
    Li, Xingyu
    Jonnagaddala, Jitendra
    Yang, Shuhua
    Zhang, Hong
    Xu, Xu Steven
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 1955 - 1963
  • [37] Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer
    McKenzie, Shaun
    Nelson, Rebecca
    Mailey, Brian
    Lee, Wendy
    Chung, Vincent
    Shibata, Stephen
    Garcia-Aguilar, Julio
    Kim, Joseph
    CANCER, 2011, 117 (24) : 5493 - 5499
  • [38] The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis
    Powers, Benjamin D.
    Felder, Seth, I
    Imanirad, Iman
    Dessureault, Sophie
    Dineen, Sean P.
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (02) : 719 - 727
  • [39] Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
    Chibaudel, Benoist
    Raeisi, Morteza
    Cohen, Romain
    Yothers, Greg
    Goldberg, Richard M.
    Bachet, Jean-Baptiste
    Wolmark, Norman
    Yoshino, Takayuki
    Schmoll, Hans-Joachim
    Kerr, Rachel
    Lonardi, Sara
    George, Thomas J.
    Shacham-Shmueli, Einat
    Shi, Qian
    Andre, Thierry
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (35)
  • [40] Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma
    Wong, William G.
    Holguin, Rolfy A. Perez
    Stahl, Kelly A.
    Olecki, Elizabeth J.
    Pameijer, Colette
    Shen, Chan
    SURGERY IN PRACTICE AND SCIENCE, 2022, 8